Peer-reviewed publications confirm the potential of Transgene's TG4001 and TG6002

information fournie par Boursorama •05/06/2019 à 17:45

Peer-reviewed publications confirm the potential of Transgene's TG4001 and TG6002

- Therapeutic vaccine TG4001, administered as a single agent, demonstrated statistically significant curative activity at 30 months in randomized Phase 2b trial in HPV-associated CIN 2/3
- Oncolytic virus TG6002 shows increased tumor selectivity and strong antitumor activity in several preclinical models


Strasbourg, France, June 5, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, announces the publication of two articles highlighting the potential of TG4001 and TG6002, two clinical-stage products, that are expected to generate new clinical data in H2 2019.

.../...